BioSpace News Archive

Owens & Minor, Inc. (NYSE: OMI) (the “Company”) today announced that it has commenced an underwritten public offering (the “Offering”) of $150,000,000 of shares of its common stock. The Company intends to grant the underwriters an option to purchase up to $22,500,000 of additional shares of common stock. The Company expects to use all or substantially all of the net proceeds from the Offering to repay debt and any rem

LUNGevity Foundation and American Cancer Society Cancer Action Network report indicates some improvement but substantial gaps still exist for many patients

CureVac N.V., a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced that the first participant has been dosed in a Phase 2a clinical trial of its COVID-19 vaccine candidate, CVnCoV.

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that the federal judge handling Catalyst’s case against the FDA has adopted the previously reported Report and Recommendation of the Magistrate Judge, granted summary judgment in favor of the FDA and Jacobus, and dismissed Catalyst’s case.

‘Clean Air for All’ online symposium highlights progress made and remaining obstacles to ensure clean air for all Americans

Surgalign Holdings, Inc. (Nasdaq: SRGA), a global pure-play spine company focused on advancing spine surgery including through the application of digital technologies to improve patient outcomes, today announces that it has entered into a definitive agreement to acquire Holo Surgical Inc., (‘Holosurgical’)

The Public Health Agency of Canada is collaborating with provincial and territorial public health partners to investigate an outbreak of Salmonella infections occurring in British Columbia, Alberta, and Yukon.

Havn Life Sciences Inc., is pleased to announce Its financial results for the three month period ended July 31, 2020.

Aptorum Group Limited announced the pricing of a public offering of 2,769,231 Aptorum’s Class A ordinary shares and warrants to purchase up to 2,769,231 Class A Ordinary Shares, at a combined public offering price of $3.25 per share and related warrant.

Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved ALKINDI® SPRINKLE (hydrocortisone) oral granules as replacement therapy for Adrenocortical Insufficiency (AI) in children under 17 years of age.